Pharmacogenomic Effect/ADR for Ribavirin (DBSNPE000239)
- Identifier
- DBSNPE000239, DBSNPE000240
- Drug
- Ribavirin (DB00811)
- Interacting Gene/Enzyme
- Interferon lambda-3
- Gene Name
- IFNL3
- UniProt ID
- Q8IZI9
- Defining Change(s)
C > T rs12979860 - Allele Name
- Not Available
- Genotype(s)
- (T;T) / (C;T) / (G;G) / (G;T)
- Type(s)
- Effect Directly Studied
- Groups
- Not Available
- Description
- Patients with this genotype in IFNL3 have a reduced likelihood of achieving sustained virologic response to ribavirin therapy.
- References
- Muir AJ, Gong L, Johnson SG, Lee MT, Williams MS, Klein TE, Caudle KE, Nelson DR: Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-alpha-based regimens. Clin Pharmacol Ther. 2014 Feb;95(2):141-6. doi: 10.1038/clpt.2013.203. Epub 2013 Oct 4. [Article]